Summary
Uveitis is an expanding market
currently dominated by corticosteroid treatment options as well as off-label
immunosuppressive and biologic drugs. Since the conventional corticosteroid
treatment is only effective in 50-60% of patients a significant number of
patients can be targeted with the new treatment options. While anterior uveitis
patients represent the majority of patients, all but one of the new treatments
in late stage clinical development target the intermediate, posterior and pan
uveitis patient segment. The uveitis market is expected to grow between 2012
and 2017, due to the introduction of biologic drugs as well as a
diversification of administrative routes. Market growth is created by the
increase in treatment costs and will continue beyond the forecasted time
period. The new treatments will target some key unmet needs but opportunities
will remain for drugs capable of permanently inhibiting ocular inflammation as
well as offering an improved safety profile.
Highlights
Key Questions Answered
* The uveitis market is marked by
the presence of a number of unmet needs in current treatments. What are the
main unmet needs in this market? Will the drugs under development fulfil the
unmet needs of the uveitis market?
* The late-stage uveitis pipeline is
filled with diverse molecules and routes of administration. Which drug will
have a significant impact on the uveitis market? Which of these drugs will have
the highest CAGR, and why?
* The current uveitis market is
dominated by corticosteroids as well as off-label immunosuppressive and
biologic drugs. How will the introduction of biologic drugs change the
treatment landscape once reimbursement is not a problem anymore? How will the
drug treatment rates change over the next five years? What are the key drivers
and barriers to this change?
Key Findings
* The main driver of the expansion
of the uveitis market will be the introduction of biologic drugs, which will
increase the market size significantly. The introduction of new ocular
administration routes will strengthen the market growth further.
* An additional driver for the
uveitis market is the assignment of orphan drug status to several uveitis
drugs.
* The biggest barrier for the
introduction of the more costly treatment options like biologics will be
reimbursement especially in the European markets. To ensure reimbursement
companies will have to work closely together with payers and price their drugs
competitively.
* Pipeline drugs developed by small
to mid-size pharma companies represent a good opportunity for companies to
enter the uveitis market and to strengthen their ophthalmology department.
Scope
* Overview of uveitis, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment
guidelines.
* Annualized uveitis therapeutics
market revenue, annual cost of therapy and treatment usage pattern data from
2012 and forecast for five years to 2017.
* Key topics covered include market
characterization, unmet needs, R&D and clinical trials assessment, late
stage clinical trial analysis and implications for the uveitis therapeutics
market.
* Pipeline analysis: focus on the
five late-stage pipeline drugs discussing emerging trends as well as overview
of earlier phase drugs.
* Analysis of the current and future
market competition in the global uveitis therapeutics market. Insightful review
of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its implications.
Reasons to buy
* Develop and design your
in-licensing and out-licensing strategies through a review of pipeline products
and technologies, and by identifying the companies with the most robust
pipeline. Additionally a list of acquisition targets included in the pipeline
product company list.
* Develop business strategies by
understanding the trends shaping and driving the global uveitis therapeutics
market.
* Drive revenues by understanding
the key trends, innovative products and technologies, market segments, and
companies likely to impact the global uveitis therapeutics market in future.
* Formulate effective sales and
marketing strategies by understanding the competitive landscape and by analyzing
the performance of various competitors.
* Identify emerging players with
potentially strong product portfolios and create effective counter-strategies
to gain a competitive advantage.
* Track drug sales in the global
uveitis therapeutics market from 2012-2017.
* Organize your sales and marketing
efforts by identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
To order this report:
US:
+1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
RELATED LINK:
RELATED VIDEO:
